Core Insights - Marriott Vacations Worldwide (VAC) is positioned to continue its earnings-beat streak, having surpassed earnings estimates by an average of 14.79% in the last two quarters [1][5]. Earnings Performance - For the most recent quarter, Marriott Vacations Worldwide reported earnings of $1.56 per share, missing the expected $1.66 per share by 6.41%. In the previous quarter, the company exceeded the consensus estimate of $1.51 per share by reporting $1.86 per share, resulting in a surprise of 23.18% [2]. Earnings Estimates and Predictions - Estimates for Marriott Vacations Worldwide have been trending higher, supported by its history of earnings surprises. The stock currently has a positive Zacks Earnings ESP of +3.71%, indicating bullish sentiment among analysts regarding its near-term earnings potential [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong likelihood of another earnings beat, with historical data showing that stocks with this combination beat consensus estimates nearly 70% of the time [6][8]. Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions. This metric is crucial for predicting earnings surprises [7][9]. Importance of Earnings ESP - While many companies may beat consensus EPS estimates, the Earnings ESP metric is essential for assessing the likelihood of such outcomes. A negative Earnings ESP does not necessarily indicate an earnings miss, but it reduces predictive power [9][10].

Core Viewpoint - Trimble Navigation (TRMB) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a solid history of exceeding expectations [1]. Company Performance - Trimble has a strong track record of surpassing earnings estimates, with an average surprise of 2.26% over the last two quarters [2]. - In the last reported quarter, Trimble achieved earnings of $0.61 per share, exceeding the Zacks Consensus Estimate of $0.59 per share, resulting in a surprise of 3.39% [3]. - For the previous quarter, the company reported earnings of $0.89 per share against an expected $0.88 per share, delivering a surprise of 1.14% [3]. Earnings Estimates - Earnings estimates for Trimble have been trending upward, influenced by its history of earnings surprises [5]. - The company currently has a positive Earnings ESP of +0.64%, indicating increased analyst optimism regarding its near-term earnings potential [8]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) suggests a strong likelihood of another earnings beat [8]. Predictive Metrics - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7]. Upcoming Events - Trimble's next earnings report is anticipated to be released on August 6, 2025 [8].

Core Insights - eBay is set to report its second-quarter 2025 results on July 30, with expected revenues between $2.59 billion and $2.66 billion, indicating a year-over-year growth of 2.91% [1][9] - Non-GAAP earnings per share are projected to be between $1.24 and $1.31, reflecting a year-over-year growth of 4% to 11% [1][9] Revenue and Earnings Expectations - The Zacks Consensus Estimate for second-quarter 2025 revenues is $2.65 billion, with earnings per share consensus at $1.30, showing a year-over-year increase of 10.17% [2] - eBay has consistently surpassed the Zacks Consensus Estimate for earnings in the past four quarters, with an average surprise of 3.11% [2] Performance Drivers - The second-quarter performance is expected to benefit from strong momentum in luxury goods, collectibles, and refurbished products, which are high-margin segments [3] - Geographic strategies, including partnerships with Facebook Marketplace and the rollout of Klarna's Buy Now, Pay Later, are anticipated to enhance eBay's reach and GMV [4] Product Innovations - eBay's introduction of the 'Magical Listing' AI tool and improvements in search and advertising are expected to enhance seller productivity and drive GMV gains [5] Shipping and Logistics - The expansion of eBay's managed shipping program in the UK is likely to simplify logistics for sellers and improve buyer trust, contributing to revenue and profitability [6] Challenges - eBay's performance may face pressure from tariff uncertainties, particularly regarding China-to-US trade, with about 5% of GMV exposed to cross-border flows [7] Earnings Model Insights - eBay currently has an Earnings ESP of +3.69% and a Zacks Rank of 2, indicating a favorable outlook for an earnings beat [10]

Key Takeaways Vale S.A. (VALE) is expected to report a decline in its bottom and top lines when it reports second-quarter 2025 results on July 31, after market close. The Zacks Consensus Estimate for Vale's sales is pegged at $8.66 billion, indicating a 12.7% decrease from the year-ago quarter's figure. The consensus mark for earnings has moved down 25% over the past 60 days to 33 cents per share. The figure indicates a 23% year-over-year decline. | | Q1 | Q2 | F1 | F2 | | --- | --- | --- | --- | --- | | Cu ...

Core Viewpoint - Unisys Corporation (UIS) is expected to report a significant decline in earnings for the second quarter of 2025, with a projected loss of 34 cents per share, compared to a profit of 16 cents in the same quarter last year, indicating a 312.5% decrease in EPS [1][5]. Financial Performance - The consensus estimate for second-quarter revenues is $442.5 million, reflecting a 7.5% decrease from the previous year's figure [5][8]. - UIS has a history of earnings surprises, having outperformed the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 46.9% [5]. Revenue Drivers - Growth in Device Subscription Services (DSS), AI-led solutions, and enterprise storage is anticipated to contribute to sequential revenue gains [8][10]. - UIS projects approximately $375 million in Ex-L&S revenues, indicating mid-single-digit sequential growth [11]. - Strength in multi-year infrastructure contracts and increased demand for PC refreshes, driven by Windows 11 and AI compatibility, are expected to support performance [12][13]. Challenges - Timing-related headwinds from license and support renewals and softness in discretionary public sector projects may hinder revenue growth [14]. - Labor and training costs associated with ramping up operations may exert pressure on margins [15]. Stock Performance and Valuation - UIS shares have increased by 9.3% over the past three months, outperforming the Zacks Computers - IT Services industry, which grew by 3.6% [16]. - The stock is currently trading at a forward price-to-sales (P/S) multiple of 0.15X, significantly below the industry average of 18.58X [19]. Strategic Positioning - UIS is focusing on expanding its presence in high-growth areas such as digital workplace services, cybersecurity, and AI-enabled solutions [21]. - The company is experiencing strong momentum in new business signings, particularly in high-volume DSS contracts [21]. Outlook - While UIS is making progress in high-growth segments, short-term pressures from license renewal timing and cautious public sector spending may impact margins and revenue momentum [24]. - The near-term earnings trajectory appears uncertain, with projected year-over-year EPS decline and modest revenue contraction [25].

Industry Overview - The second-quarter 2025 reporting cycle for the Medical sector is commencing, with most firms expected to release earnings results in the next two weeks, primarily consisting of pharma/biotech and medical device companies [1] - The earnings season for the drug and biotech sector began in mid-July, highlighted by Johnson & Johnson's strong performance, which exceeded earnings and sales estimates, leading to raised revenue and earnings expectations for the year [1] Company Performance - Novartis surpassed second-quarter earnings and revenue estimates, driven by a year-over-year increase in sales of key drugs, prompting an upward revision of its annual guidance for core operating income [2] - Roche experienced solid growth in the first half of 2025, with high demand for key drugs offsetting declines in legacy drug sales [2] - As of July 23, 15% of companies in the Medical sector, representing 27.2% of the sector's market capitalization, reported quarterly earnings, with 88.9% outperforming earnings estimates and 100% beating revenue estimates [3] - Overall, second-quarter earnings for the Medical sector are projected to increase by 0.9%, while sales are expected to rise by 7.9% compared to the previous year [3] Upcoming Earnings Reports - Merck, AstraZeneca, Bristol Myers, AbbVie, and Moderna are scheduled to release their quarterly results this week [4] - Merck has a strong earnings track record, beating estimates in the last four quarters with an average surprise of 3.82% [5] - AstraZeneca has a mixed earnings history, beating estimates in three of the last four quarters, with an average surprise of 4.24% [8] - Bristol Myers has consistently beaten earnings estimates, with an average surprise of 20.16% over the last four quarters [11] - AbbVie has also maintained a strong track record, beating estimates in the last four quarters with an average surprise of 2.55% [13] - Moderna has an excellent earnings history, with an average surprise of 31.60% in the last four quarters [15] Sales Drivers - Merck's growth in the second quarter is likely attributed to increased sales of its cancer drug Keytruda, driven by additional indications and patient demand [7] - AstraZeneca's sales are expected to be bolstered by strong demand for its cancer and diabetes medications [10] - Bristol Myers' revenue may be impacted by declines in legacy drug sales, but growth products are expected to partially offset this decline [12] - AbbVie's revenue is anticipated to be driven by strong sales of key drugs and contributions from newer products [14] - Moderna's revenues are expected to be influenced by sales of its COVID-19 vaccine, Spikevax, while the focus is shifting to updates on its broader pipeline [16]

Core Insights - Arthur J. Gallagher & Co. (AJG) is anticipated to show improvements in both revenue and earnings for Q2 2025, with revenue expected to reach $3.17 billion, reflecting a 15.8% year-over-year growth [1] - The earnings consensus estimate is $2.36 per share, indicating a 4.4% increase from the previous year, although this estimate has decreased by 0.8% in the last 30 days [2] Financial Performance Expectations - The Zacks Consensus Estimate for fees is projected at $925 million, representing a 12% increase from the prior year, while commissions are expected to reach $1.8 billion, indicating a 12.5% growth [6] - Factors contributing to the expected performance include strong client retention, new business generation, and higher renewal premiums across AJG's business lines [5][7] Earnings Prediction Model - The current model does not predict an earnings beat for AJG, as it has an Earnings ESP of -0.05% and a Zacks Rank of 4 (Sell) [3][4] Segment Performance - The Risk Management segment is expected to benefit from excellent client retention and increased customer business activity [6] - The Brokerage segment is likely to see improvements due to higher new business generation and increased interest income [7] Expense Outlook - Total expenses are anticipated to rise primarily due to increased compensation, reimbursements, and changes in estimated acquisition earnout payables [8]

Core Insights - Carpenter Technology Corporation (CRS) is set to report its fourth-quarter fiscal 2025 results on July 31, with sales estimated at $770 million, reflecting a 3.6% decrease from the previous year [1] - The earnings consensus estimate for CRS is $2.03 per share, indicating an 11.5% year-over-year growth, with a 0.5% increase in the estimate over the past 60 days [1][4] - CRS has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 11.1% [3][4] Financial Performance Expectations - The Specialty Alloys Operations segment is expected to report sales of $689 million, down 3.7% year-over-year, with an operating profit projected at $163 million, up from $141 million in the same quarter last year [9] - Performance Engineered Products' net sales are anticipated to rise 1.5% year-over-year to $113 million, with an operating profit expected to increase to $11.7 million from $10.6 million [10] Market Dynamics - Demand in aerospace, defense, and medical applications is expected to support CRS's performance, despite challenges from labor and chip shortages [7][8] - Increased productivity, higher prices, and an improved product mix are likely to have positively impacted margins, countering the effects of soft sales volume [8] Stock Performance - CRS shares have increased by 97.4% over the past year, significantly outperforming the industry growth of 46.7% [11]

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 4, might help the stock move higher if these key numbers are better than ...

Core Viewpoint - Crescent Energy (CRGY) is expected to report a year-over-year decline in earnings despite higher revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is anticipated on August 4, with expected earnings of $0.23 per share, reflecting a year-over-year decrease of 25.8% [3]. - Revenues are projected to be $895.46 million, which is an increase of 37.1% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 17.02% higher in the last 30 days, indicating a reassessment by analysts [4]. - Crescent Energy's Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of actual earnings deviating from consensus estimates, with a positive reading being a strong predictor of an earnings beat [9][10]. - Crescent Energy currently holds a Zacks Rank of 1, but the combination with a 0% Earnings ESP makes it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, Crescent Energy exceeded the expected earnings of $0.47 per share by delivering $0.56, resulting in a surprise of +19.15% [13]. - The company has beaten consensus EPS estimates in all of the last four quarters [14]. Market Reaction Factors - An earnings beat or miss may not solely dictate stock movement, as other factors can influence investor sentiment [15]. - Despite not appearing as a compelling earnings-beat candidate, other market conditions should be considered when evaluating Crescent Energy [17].